Olivia Pagani
Expertise in
5
conditions

Olivia Pagani

Le Vaud, VD, CH 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
5
conditions
Le Vaud, VD, CH 

Overview

Olivia Pagani practices in Le Vaud, Switzerland. Ms. Pagani is highly rated in 5 conditions, according to our data. Her top areas of expertise are Breast Cancer, Menopause, HER-2 Positive Breast Cancer, Oophorectomy, and Mastectomy.

Her clinical research consists of co-authoring 144 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Le Vaud, VD, Switzerland
Other Locations
Geneve, GE, Switzerland
Bern, BE, Switzerland
Rennaz, VD, Switzerland
Lugano, TI, Switzerland
Bellinzona, TI 6500, Switzerland
Switzerland
Viganello, TI, Switzerland
Sankt Gallen, SG, Switzerland
Locarno, TI, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Other
The DIALOGUE Study: Using Digital Health to Improve Care for Families With Predisposition to Hereditary Cancer
The DIALOGUE Study: Using Digital Health to Improve Care for Families With Predisposition to Hereditary Cancer
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Other
Study Phase: Not Applicable
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 3
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Study Drugs: Paclitaxel, Trastuzumab, Pertuzumab, Palbociclib, Letrozole
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A 24 Weeks Activity Program in Patients With Early Breast Cancer Receiving Aromatase Inhibitor Therapy. A Multicenter Randomized Phase III Trial
A 24 Weeks Activity Program in Patients With Early Breast Cancer Receiving Aromatase Inhibitor Therapy. A Multicenter Randomized Phase III Trial
Enrollment Status: Completed
Publish Date: June 27, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer
A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer
Enrollment Status: Terminated
Publish Date: June 27, 2023
Intervention Type: Drug
Study Drug: CR1447
Study Phase: Phase 2
Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Drug
Study Drug: Eribulin Mesilate
Study Phase: Phase 2
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.
Enrollment Status: Terminated
Publish Date: June 16, 2021
Intervention Type: Other, Drug
Study Drug: Ribociclib
Study Phase: Phase 3
View 8 Less Clinical Trials

143 Total Publications

Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.
Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.
Journal: Breast (Edinburgh, Scotland)
Published: November 21, 2025

Frequently Asked Questions about Olivia Pagani

Is Olivia Pagani a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Olivia Pagani is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olivia Pagani participate in research or clinical trials?

Yes. Olivia Pagani has published 143 articles and abstracts on conditions like Breast Cancer. You can view a list of Olivia Pagani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pagani's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile